Menu
23/06/2003
Scientists identify gene that can 'stop' ovarian cancer
Cancer Research UK scientists have claimed to have isolated a gene that has the power to stop ovarian cancer developing, according to a report published yesterday.
Researchers found that the gene, known as OPCML, was "switched off" in almost 90% of the ovarian tumours that were tested. And experiments in the laboratory have shown that when fully functioning OPCML genes are inserted into human ovarian cancer cells tumour growth is dramatically suppressed.
Dr Hani Gabra, who led the research at Cancer Research UK's Edinburgh oncology unit, said: "This is a very important discovery in identifying what seems to be a key tumour suppressor gene in ovarian cancer.
"We have found that these genes are frequently 'switched off' at very early stages of the disease and fail to make essential proteins. But when we switch these genes back on in the cancer cells tumours are suppressed.
In normal ovarian tissue, OPCML seems to prevent cells from being cancerous but defects in the gene may open the way for development of the disease.
Scientists believe it may be possible to devise drugs to mimic the effects of OPCML in order to block the growth of ovarian cancer cells.
Ovarian cancer has no obvious symptoms in the early stages and is particularly difficult to detect. There is no effective screening procedure that can indicate pre-cancerous cells as there is in cervical and bowel cancer.
Dr Grant Sellar, who also worked on the report, said: "This is an exciting development in our understanding of the early stages of ovarian cancer. Now we need to work on learning more about the function of OPCML and how it works in relation to ovarian cancer."
The lifetime risk for a woman in England or Wales developing ovarian cancer is 1 in 48. In the UK in 2000, there were 4,431 deaths from ovarian cancer – 3,909 in England and Wales, 442 in Scotland and 100 in Northern Ireland.
Five-year survival in England, Wales and Scotland is around 29%, and in Northern Ireland it is around 27%. Sweden has the best five-year survival rate in Europe at 45%.
(GMcG)
Researchers found that the gene, known as OPCML, was "switched off" in almost 90% of the ovarian tumours that were tested. And experiments in the laboratory have shown that when fully functioning OPCML genes are inserted into human ovarian cancer cells tumour growth is dramatically suppressed.
Dr Hani Gabra, who led the research at Cancer Research UK's Edinburgh oncology unit, said: "This is a very important discovery in identifying what seems to be a key tumour suppressor gene in ovarian cancer.
"We have found that these genes are frequently 'switched off' at very early stages of the disease and fail to make essential proteins. But when we switch these genes back on in the cancer cells tumours are suppressed.
In normal ovarian tissue, OPCML seems to prevent cells from being cancerous but defects in the gene may open the way for development of the disease.
Scientists believe it may be possible to devise drugs to mimic the effects of OPCML in order to block the growth of ovarian cancer cells.
Ovarian cancer has no obvious symptoms in the early stages and is particularly difficult to detect. There is no effective screening procedure that can indicate pre-cancerous cells as there is in cervical and bowel cancer.
Dr Grant Sellar, who also worked on the report, said: "This is an exciting development in our understanding of the early stages of ovarian cancer. Now we need to work on learning more about the function of OPCML and how it works in relation to ovarian cancer."
The lifetime risk for a woman in England or Wales developing ovarian cancer is 1 in 48. In the UK in 2000, there were 4,431 deaths from ovarian cancer – 3,909 in England and Wales, 442 in Scotland and 100 in Northern Ireland.
Five-year survival in England, Wales and Scotland is around 29%, and in Northern Ireland it is around 27%. Sweden has the best five-year survival rate in Europe at 45%.
(GMcG)
Related UK National News Stories
Click here for the latest headlines.
01 June 2015
Scientists Discover Radiotherapy Improvements For Cancers
Scientists from Cancer Research UK have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation.
Scientists Discover Radiotherapy Improvements For Cancers
Scientists from Cancer Research UK have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation.
10 July 2009
Gene Defect Linked To Allergy, BMJ Finds
Defects in a particular gene - the filaggrin gene - are associated with a significantly increased risk of developing allergic disorders such as eczema, rhinitis, and asthma, concludes a study published on bmj.com today. Allergic diseases have increased in recent decades and now affect up to one in three children in economically developed countries.
Gene Defect Linked To Allergy, BMJ Finds
Defects in a particular gene - the filaggrin gene - are associated with a significantly increased risk of developing allergic disorders such as eczema, rhinitis, and asthma, concludes a study published on bmj.com today. Allergic diseases have increased in recent decades and now affect up to one in three children in economically developed countries.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
24 June 2003
£50m funding unveiled for NHS gene research
The government is set to promote the development of genetics within the NHS following its decision to plough £50 million into the scheme over the next three years. The White Paper 'Our Inheritance, Our Future - Realising the potential of genetics in the NHS' sets out the government's strategy.
£50m funding unveiled for NHS gene research
The government is set to promote the development of genetics within the NHS following its decision to plough £50 million into the scheme over the next three years. The White Paper 'Our Inheritance, Our Future - Realising the potential of genetics in the NHS' sets out the government's strategy.
08 August 2011
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
-
Northern Ireland WeatherThis Evening and Tonight:Showers, scattered in the evening, will clear by midnight leaving the night dry with clear spells. Perhaps a touch of ground frost. Cloud will spread east towards morning. Minimum temperature 2 °C.
